Indivior Pharmaceuticals, Inc. Share Price & Technical Analysis
INDV · $38.07 (-0.73%)
Healthcare / Drug Manufacturers - Specialty & Generic
$38.07
-0.73%
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE bu…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
0% return in May, 3% avg return in past 3 year May month.
5% return in 2026, 32% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -1% | -8% | -6% | 19% | 0% | – | – | – | – | – | – | – | 5% |
| 25 | -6% | -21% | 0% | 20% | 11% | 17% | 37% | 20% | -1% | 23% | 12% | 7% | 118% |
| 24 | 15% | 22% | -4% | -19% | 3% | -11% | -10% | -8% | -20% | -7% | 23% | 12% | -5% |
| 23 | 11% | -23% | -9% | 12% | -4% | 31% | -4% | -3% | 1% | -13% | -12% | -6% | -18% |
| 22 | -16% | 22% | 4% | 7% | 6% | -11% | 2% | -8% | -14% | 33% | 6% | 4% | 36% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Strong
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.51B
P/E ratio
19.56
52W high
$41.00
52W low
$10.63
Volume
5,18,338
Beta
1.20
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Indivior Pharmaceuticals, Inc. share price today?
- Indivior Pharmaceuticals, Inc. (INDV) last traded around $38.07 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does INDV have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for INDV. Download the app for real-time alerts.
- How can I analyze Indivior Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.